Investigational drug · Phase 2
AK127
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatocellular Carcinoma, Advanced Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "AK127"
First trial start
2023
Oct 16, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AK127", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma
- Advanced Solid Tumors
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AK127" as an intervention, largest first.
- A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)Pivotal-lookingRecruiting
AkesoIndustry
NCT06530251 · 280 participants (planned) · Start Sep 24, 2024 · Primary completion Jun 2026
Drug: AK112; Cadonilimab and 4 more · For: Hepatocellular Carcinoma
Sites: Beijing, China; Jinan, China
- A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid TumorsActive, not recruiting
AkesoIndustry
NCT05951608 · 216 participants (planned) · Start Oct 16, 2023 · Primary completion May 1, 2026
Drug: AK127 in combination with AK112 · For: Advanced Solid Tumors
Sites: Harbin, China
AkesoIndustry
NCT05868876 · 70 participants · Start Jul 26, 2023 · Primary completion Mar 4, 2026
Drug: AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion · For: Advanced Malignant Tumors
Sites: Tianjin, China
Akesobio Australia Pty LtdIndustry
NCT05021120 · 67 participants · Start Oct 12, 2021 · Primary completion Oct 1, 2024
Drug: AK127; AK104 · For: Advanced or Metastatic Solid Tumours
Sites: Adelaide, Australia; Melbourne, Australia; Sydney, Australia · 5 sites in all
- A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid TumorsStatus unknown
AkesoIndustry
NCT05393063 · 36 participants (planned) · Start Jun 2022 · Primary completion Jun 2023
Drug: AK127 · For: Advanced Solid Tumors
Newest research
PubMed records naming it or its code names, newest first.
- Ədentification of SQ109 analogs with enhanced antimicrobial activity against methicillin-resistant Staphylococcus aureus.
Dellis C, Laros G, Georgiou K, et al. · Antimicrob Agents Chemother 2026
- LagC is required for cell-cell interactions that are essential for cell-type differentiation in Dictyostelium.
Dynes JL, Clark AM, Shaulsky G, et al. · Genes Dev 1994
Also in development for Hepatocellular Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.